Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

SBRT Appears to Be Safe, Feasible in Oligometastatic Disease With Multiple Metastases

May 20th 2021

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Prophylactic Pelvic Radiotherapy Significantly Improves Biochemical Failure-Free Survival, DFS in High-Risk Prostate Cancer

May 20th 2021

Prophylactic whole-pelvic radiotherapy improved biochemical failure-free survival and disease-free survival vs prostate-only radiotherapy in patients with high-risk, locally advanced prostate cancer.

Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans

May 19th 2021

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

May 19th 2021

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Dr. Ward on Adding Systemic Therapy to Radiation Therapy in Prostate Cancer

May 18th 2021

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

Dr. Horwitz on the Evolution of Radiation Therapy in Prostate Cancer

May 14th 2021

Eric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.

Dr. Gomella on Using Novel Biomarkers to Inform Biopsy Vs Observation in Prostate Cancer

May 14th 2021

Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.

18F-Fluciclovine-PET/CT Plus Conventional Imaging Improves Survival With Radiotherapy in Prostate Cancer

May 14th 2021

The use of 18F-fluciclovine-PET/CT in guiding salvage treatment with radiotherapy after prostatectomy reduced the likelihood of biochemical recurrence or suboptimal response to treatment in patients with prostate cancer without evidence of extrapelvic disease with conventional imaging.

Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer

May 12th 2021

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

FDA Grants Breakthrough Device Designation to AI-Based Focal Therapy System in Prostate Cancer

May 11th 2021

The FDA has granted a breakthrough device designation to the Avenda Health Focal Therapy System, a male “lumpectomy” product under development to treat patients with prostate cancer in office while preserving quality of life.

Dr. Zhu on Stratifying Treatments in Node-Positive Prostate Cancer

May 10th 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

Enzalutamide Approved in Europe for Metastatic Hormone-Sensitive Prostate Cancer

May 4th 2021

The European Commission has approved enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

Masitinib Plus Docetaxel Improves PFS in Metastatic Castration-Resistant Prostate Cancer

April 30th 2021

The novel oral TKI masitinib in combination with docetaxel and prednisone resulted in improved progression-free survival compared with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, meeting the predefined primary end point of the phase 2b/3 AB12003 trial.

PARP Inhibitors Pave Way for Personalized Care in CRPC

April 30th 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

Increased Somatically Acquired Alterations May Lead to More Aggressive Prostate Cancer, Mortality in Black Patients

April 29th 2021

A higher incidence of somatically acquired genetic alterations, including damaging mutations in ZMYM3 leading to genomic instability, as well as deletions in MAP3K7, BNIP3L, RB1, and NEIL3, and gain of MYC, may lead to more aggressive prostate cancer in Black/African American men.

Dr. Choudhury on Future Research Directions for Pembrolizumab/Radium-223 in mCRPC

April 26th 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Apalutamide Maintains OS Benefit in Castration-Sensitive Prostate Cancer

April 26th 2021

Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.

Earlier Administration of Antiandrogens May Further Delay Disease Progression in Nonmetastatic CRPC

April 26th 2021

Natasha Garg, DO, discusses the impact of antiandrogens in the treatment of patients with nonmetastatic CRPC, shared advice for choosing among the available options, and projected what the future paradigm might look like.

One-Size-Fits-All Treatment Is Not Appropriate in Node-Positive Prostate Cancer

April 24th 2021

Jason Zhu, MD, discusses the need to tailor therapy with androgen-deprivation therapy, radiation, and antiandrogen agents for men with pathologic and clinical node-positive prostate cancer.

Dr. Ward on Considerations for Salvage Radiation Therapy in Prostate Cancer

April 23rd 2021

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.